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Stroke, the third leading cause of mortality, is usually associated with severe disabilities, high recurrence rate and
other poor outcomes. Currently, there are no long-term effective treatments for stroke. Cell and cytokine therapies
have been explored previously. However, the therapeutic outcomes are often limited by poor survival of transplanted
cells, uncontrolled cell differentiation, ineffective engraftment with host tissues and non-sustained delivery of growth
factors. A tissue-engineering approach provides an alternative for treating ischemic stroke. The key design considerations
for the tissue engineering approach include: choice of scaffold materials, choice of cells and cytokines and delivery
methods. Here, we review current cell and biomaterial based therapies available for ischemic stroke, with a special focus
on tissue-engineering strategies for regeneration of stroke-affected neuronal tissue.
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Introduction
Stroke is the third leading cause of disease mortality
worldwide. In the United States, about 150,000 indivi-
duals die of stroke every year [1]. Ischemic stroke is caused
by interruption of the cerebral blood supply, accounting for
about 80% of all stroke cases [2]. Depending on the regions
where ischemic stroke occurs, it can impair patients’ ca-
pabilities of sensory processing, communication, cognition
and motor function [3]. Motor impairment associated with
stroke often leads to short-term or permanent disabilities, sub-
stantially affecting patients’ life quality [4]. In addition, stroke
increases the risk of Parkinson’s disease and Alzheimer’s
disease [5].
Currently, there are no long-term effective clinical
treatments available for stroke as few of them leads
to complete functional recovery [6,7]. The intravenous ad-
ministration of tissue-type plasminogen activator (tPA) is
a proven intervention for acute ischemic stroke patients
[8]. However, this treatment is only applicable to a small* Correspondence: katelinwang@gmail.com
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reproduction in any medium, provided the orpercentage of stroke patients in the acute phase as its
therapeutic time window is rather narrow (up to 4.5 hours
after the onset of symptoms) [9]. Meanwhile, this treat-
ment was reported to increase the risk of intracranial
hemorrhage [10]. Physical therapy is often used to restore
motor function after stroke [4,11,12]. However, 15–
30% of stroke patients are still permanently disabled even
with intensive task-specific training [4,13]. Early motor
training and physical therapy might impede functional
recovery and enlarge lesion size as suggested by animal
experiments [14,15]. Thus, few of these treatments can
lead to complete functional recovery. Cell and cytokine
therapies [16-23] have been explored previously. The
regeneration outcome of this therapy is often limited
due to poor cell survival, uncontrolled in vivo differen-
tiation of delivered cells, ineffective integration of delivered
cells with the host tissue and non-sustained delivery of
growth factors.
These limitations may be overcome by employing a
tissue engineering strategy. Tissue-engineered scaffolds
can provide a highly biocompatible three-dimensional
environment that supports the long-term growth of thera-
peutic cells seeded on the scaffolds, thus improving the
in vivo survival of these cells. Meanwhile, the scaffold can
act as a drug delivering vehicle releasing neuro-protective
factors in a controlled manner, which promotes the regen-
eration and functional recovery of damaged neuronal tissuetd. This is an open access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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ischemic stroke, with a special emphasis on the im-
portant aspects of the tissue-engineering strategy for stroke
treatment.
Cell therapy
Various types of cells have been investigated for their
potential to regenerate damaged neural tissue caused by
ischemic stroke (Table 1).
Neural stem cells
Neural stem cells (NSCs) can be obtained from along
the entire neuraxis of adult central nervous system
(CNS) [24-27]. NSCs have been experimentally utilized
to treat CNS disorders, including stroke [28,44]. The
intracranial injection of NSCs isolated from rat subven-
tricular zone (SVZ) into a rat stroke model, middle cere-
bral artery occlusion (MCAO), led to sensory and motor
recovery [28].
Human neural stem cells (hNSCs) have also been
applied into the treatment of neuronal disorders. These
cells are isolated from the embryonic or fetal CNS [44].
The human neurospheres derived from these hNSCs can
survive robustly in naive and ischemic brains [20]. When
hNSCs were injected directly into the stroke-damaged
striatum of adult rats, these cells differentiated and
expressed mature neuronal markers, such as calbindin,
HuD and parvalbumin [45], indicating that transplanted
NSCs remain competent to differentiate into functional
neurons. This result is consistent with another study,
which showed that after implanted into the damagedTable 1 Cell therapy used in the treatment of stroke
Stem cell Source Function
Neural stem cells Neuraxis of adult CNS Differentiate into three CNS c





Bone marrow Differentiate into osteoblas
chondroblasts, adipocytes,




Nasal olfactory mucosa Guide axon outgrowth and
remyelinate axons and sec
many trophic factors (inclu
BDNF, VEGF and glial cell
neurotrophic factor (GDNF
Dental stem cells Dental pulp (dental pulp
stem cells) as well as
dental follicle cells
Differentiate into neural ce
osteocytes, adipocytes, chond
muscle cells and hepatocytes
and in vivo; express neuro
factors such as GDNF, BDN
nerve growth factor (NGF); pr
angiogenesiscentral nervous system of ischemic rats, a fraction of the
grafted neural stem cells were able to differentiate into
neurons in vivo and promote function recovery [29].
Although NSCs showed a great potential in treating cere-
bral ischemic lesion, many problems remain, for instance,
the low in vivo survival rate of these cells, immune rejec-
tion and ethical issues.
Mesenchymal stem cells
Mesenchymal stem cells (MSCs), presented in the bone
marrow, are multipotent adult stem cells with the capabil-
ities of differentiating into various cell types, including neu-
rons [31,32]. MSCs can differentiate into neurons in vitro
in an experimentally controlled manner. When cultured
with differentiation factors (e.g. β-mercaptoethanol and
dimethylsulfoxide) [32], growth factors (e.g. fibroblast
growth factor-2 (FGF2) and epidermal growth factor
(EGF) [46], brain-derived neurotrophic factor (BDNF)
[47] or retinoic acid (RA) [48]), these MSCs express
neuronal markers (neuron-specific endonuclease, NeuN
neurofilament-M, glial fibrillary acidic protein (GFAP),
tyrosine hydroxylase, and β-III-tubulin) [46]. MSCs were
reportedly to be able to survive and migrate into lesion
sites after transplanted into the experimental models of
stroke [49]. Moreover, the intravenous injection of MSCs
was found to promote functional recovery in the animal
stroke MCAO model [33]. This function recovery re-
sulted from MSCs treatment may be associated with
reduced scar thickness and the increased number of
oligodendrocyte precursor cells and proliferating cells
along the SVZ [34]. Notably, the therapeutic effects ofSpecies Model Effects Refs.
ell types
ding
Rat MCAO Behavioral recovery on a series
of sensory tasks and motor tasks;
neural stem cells differentiated
into neurons and promote
function recovery
[24-30]
ts, Rat MCAO Behavioral recovery; facilitated
functional recovery; reduced scar
thickness and increased number
of oligodendrocyte precursor







Rat MCAO The combined transplantation
of OECs with fibroblasts
facilitated neurite outgrowth









Rat MCAO Functional recovery was
observed in one motor task;
surviving cells may have
differentiated into neurons
[40-43]
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clinical trials. In a small trial, the intravenous infusion of
autologous MSCs significantly improved functional re-
covery without obvious adverse effects during one-year
follow-up [50]. Similar recovery effects were also ob-
served in a long-term clinical trial with 52 stroke patients
[51]. Compared with NSCs, MSCs appear to be more
conveniently obtained. Autologous MSCs can reduce
immunologic rejection and bypass ethical issues. None-
theless, like NSCs, the application of MSCs for stroke
treatment faces the similar challenges, such as poor in vivo
cell viability.
Stimulation of endogenous neurogenesis
While stroke patients may benefit from neuronal regen-
eration mediated by exogenously delivered stem cells,
stimulating endogenous neurogenesis by activating brain
resident cells for neuronal repair can be another poten-
tial approach for treating stroke. In response to stroke or
other brain injury, the degree of endogenous neurogen-
esis, neurite outgrowth and functional recovery are often
constrained [52-56]. There are two main regions of the
adult brain that contain proliferating progenitor cells:
the SVZ and the subgranular zone (SGZ) [57]. While
under normal conditions the quiescent ependymal cells
do not contribute to neurogenesis, these cells can be
activated to give rise to neuroblasts and astrocytes in re-
sponse to stroke [58]. One way to stimulate endogenous
neurogenesis in the SVZ is reportedly to use BDNF
fused with a collagen-binding domain (CBD-BDNF) as a
stimulant [59]. The injection of CBD-BDNF into the lat-
eral ventricle of MCAO rats was shown to promote local
neural regeneration, angiogenesis and improve functional
recovery [59].
Induced pluripotent stem cells
Dating back to the recent breakthroughs in the stem cell
field, induced pluripotent stem (iPS) cells, one of the
most exciting improvements, have been generated from
a host of human somatic cells since their original
characterization in 2007 [60]. The obvious similarities they
share with embryonic stem cells, including the ability to
differentiate into all cell types composing the tissues of the
body, turn out to be much remarkable.
It seems more attractive to clinical applications as iPS
cells generated from a patient can be applied for treat-
ment of various diseases in an autologous manner.
Transplantation of iPS cells has been experimentally
tested for treating stroke. A mixture containing iPS cells
and fibrin glue was delivered into the subdural space fol-
lowing MCAO. This treatment decreased total infarct
volume and significantly improved the motor function
(rotarod and grasping tasks) [61]. A notable reduction in
pro-inflammatory cytokines and a simultaneous increasein the anti-inflammatory cytokines were also observed
[61]. However, another study showed the formation of
tridermal teratoma in the brain after being transplanted
with undifferentiated iPS cells into the ipsilateral striatum
and the cortex of rats following the transient MCAO [62].
Although the control over in vivo differentiation of iPS
cells needs further study, it is undeniable that iPS cells will
continue to be a focus of the cell therapy for a variety of
neurodegenerative diseases, including stroke [63].
Biomaterials
A plethora of biomaterials have been investigated for
their potential to treat stroke (Table 2) [64]. An ideal
biomaterial for stroke treatment is expected to meet sev-
eral requirements: first, it must have specific physical and
biochemical properties allowing cell to attach to it, prolif-
erate and differentiate on it, migrate off to integrate with
host neuronal tissue [16,17]. Second, it should degrade
in vivo to permit tissue healing and growth. Moreover,
its degradation products should be highly biocompatible,
non-cytotoxic, non-inflammatory and non-hemolytic [16],
causing no adverse effects on implanted tissues. This bio-
material can be designed to encapsulate drugs or mole-
cules. The advantages of the encapsulation of therapeutic
chemicals are obvious, including stabilizing the drugs that
may have a short half-life, enabling the controlled release
of therapeutic factors, limiting additional damages to
healthy tissues and reducing side effects [65-67]. A number
of biomaterials have been explored for the repair of ische-
mic lesion in animal models (Table 2). Here, we will ex-
plore these biomaterial-based therapies for stroke with the
emphasis on the materials.
HAMC
Owing to versatile forms and composition, polymer-
based hydrogels have been widely used in many fields,
including neural tissue engineering [16,76-78]. Hydro-
gels are polymeric materials with high water content
(i.e. >90% water) and diverse physical properties [79].
Hyaluronan/methyl cellulose (HAMC), an injectable
hydrogel, has been used to achieve a short-term controlled
delivery of erythropoietin (EPO) in the stroke treatment
[73]. The local release of EPO from this HAMC was found
to promote endogenous neurogenesis of the SVZ and
tissue repair after stroke injury in the mouse brain.
Alginate
Alginate is naturally derived polysaccharides from brown
algae [80] and has been extensively used as hydrogel
synthetic extracellular matrix (ECM) [81-84]. As a bio-
material, alginate is applied in pharmaceutical industry
due to its mechanical and chemical stability and high
biocompatibility [85].The utilization of an alginate hydrogel
encapsulating VEGF was shown to induce structural and
Table 2 Biomaterials used in the treatment of stroke
Materials Species Model Effects Functional recovery Refs.
HAMC + PLGA + EGF-PEG + EPO Mouse Endothelin-1 induced small
cortical infarcts
Led to neural tissue repair N.A. [68]
PLGA-PEG + T3 Mouse MCAO A 34% decrease in tissue infarction
and a 59% decrease in brain edema
N.A. [69]
Collagen type I + NSCs Rat MCAO NSCs survived, differentiated and
formed synapses in the brain
Function outcome is improved
in neurological severity score
[70]
Hyaluronan-Heparin-




Promoted survival of NPCs and
diminished the infiltration of
Microglia/Macrophage cells
N.A. [71]
Alginate + VEGF Rat MCAO Reduced the lesion volume Function outcome is improved
in bias swing test and
neurological severity score
[72]
PLGA + hNSCs + VEGF Rat MCAO Attracted host endothelial cells (ECs)
and developed a vascular network
within de novo tissue
N.A. [22]
HAMC + EPO Mouse Endothelin-1 induced
small cortical infarc
Attenuated inflammatory responses;
reduced stroke cavity size; increased






Rat MCAO Supported cell migration, development
and neural regeneration in the brain
Ameliorated the disabled
function of the impaired
forelimb
[74]
PGA + NSCs Mouse Hypoxia induced ischemic Promoted neuronal differentiation;
enhanced elaboration of neural
processes; fostered re-formation
of cortical tissue and reduced
inflammation and scarring
N.A. [75]
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rat MCAO model [72].
Collagen
Collagen, the main component of the extracellular
matrix, can provide a proper surface for cell adhesion
and migration [86]. Because of its advantages in bio-
logical compatibility, mechanical strength, degradability
and immunogenicity [87,88], collagen has been widely used
in biomedical applications, including stroke treatment. A
hyaluronan-heparin-collagen hydrogel seeded with stem
cells was transplanted into the infarct cavity after stroke,
leading to improved stem cell survival and reduced damage
to the brain tissue [71]. When collagen type I and NSCs
were combined and transplanted in vivo to treat cerebral
ischemic injury, NSCs were found to differentiate and
form new synapses. This treatment promoted the struc-
tural and functional repair of brain tissue following ische-
mic stroke [70].
PLGA
Poly (D, L-lactic acid-co-glycolic acid)(PLGA) is a fully
degradable biomaterial with the end products, CO2 and
H2O [89]. PLGA particles can be readily obtained using
a single oil-in-water emulsion technique. PLGA scafolds
can act as a structural support for neural stem cells toenhance brain repair [90]. The implantation of PLGA
particles into the brain does not induce adverse host cell
responses, such as glial scar and inflammation [89], indi-
cating the excellent biocompatibility of PLGA.
PLGA particles have been used as a vehicle for deliver-
ing a number of therapeutic factors for stroke treatment,
for instance, PLGA-PEG encapsulating T3 (thyroid
hormone) [69]. This PLGA-based treatment led to a de-
crease in tissue infarction and brain edema. In another
stroke treatment, pegylated EGF (PEG-EGF) and EPO were
loaded in PLGA nanoparticles and biphasic microparticles
(a PLGA core and a poly(sebacic acid) shell), respectively,
which were dispersed in an HAMC) hydrogel. This
drug delivery system reduced the inflammatory responses
and significantly improved neurogenesis [68]. In
addition to carrying cytokines, PLGA particles can also
be used to deliver stem cells for the therapeutic purpose.
hNSCs were seeded onto VEGF-releasing PLGA particles.
This cell-cytokine-biomaterial system was found to attract
host endothelial cells and promote the development of a
local vascular network [22].
Neuro-protective factors
A wide range of neuro-protective factors, including
BDNF, GDNF, EPO and NGF (Table 3), have been uti-
lized in treating stroke in animal models [73,91,92].
Table 3 Neuro-protective factors used in the treatment of stroke
Species Model Neuro-protective factors Effects Functional recovery Refs
Rat MCAO BDNF Regulated neuronal survival, migration,
differentiation and synaptic function;
reduced infarct size
N.A. [97]
Rat MCAO GDNF Promoted neuronal survival; regulated
migration and differentiation of several
peripheral neurons
N.A. [98-104]
Rat MCAO EPO Promoted the differentiation and
proliferation of erythroid progenitor
cells; improved the survival of maturing
cells; enhanced angiogenesis and
neurogenesis
Improved neurological outcome
on the foot fault and corner tests
[105,106]
Rat MCAO EPO + hCG Decreased the total infarct volume Improved composite neurological
score and forelimb placing
behavioral outcome
[107]
Rat PVD lesion of motor
and sensory cortex
EPO + EGF Promoted migration of SVZ NPCs
to infarct sizes; differentiated into
neurons and astrocytes; enhanced
cortical regeneration
Showed improvement in cylinder
test and swimming task
[108]
Rat MCAO FGF2 Reduced infarct volume; improved
neurobehavioral and histological
outcomes; increased the number
of SVZ newborn neurons
Acquired better symmetry of
movement and forepaw
outstretching in aged rats
[109]
Rat MCAO FGF2 + platelet-poor plasma
(PPP) + platelet lysate (PLT)
Increased SVZ endogenous neural stem
cells (eNSC) proliferation, angiogenesis,
neurogenesis and neuroprotection
Functional outcome was
significantly improved for the
neurological severity score
[110]
Rat MCAO TGF-alpha Regulated migration and differentiation
of the newly generated neurons;
enhanced neurogenesis
The asymmetric behavioral
outcomes were improved in the
corner test and the cylinder test.
[111]
Rat MCAO G-CSF Reduced infarct volume N.A. [112]
Rat MCAO NGF Reduced apoptotic cell death after
ischemic injury
N.A. [113]
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esis mediated by endogenous NPCs and the survival,
proliferation and differentiation of transplanted neural
cells [93-96]. Thus, these factors play a critical role in
stroke treatment.
BDNF
Brain-derived neurotrophic factor (BDNF), a secreted
neurotrophin, regulates neuronal survival, migration, dif-
ferentiation and synaptic function [114,115] by binding
to the tropomyosin receptor kinase B (TrkB) [116].
BDNF/TrkB signaling modulates synaptic strength and
supports the survival of cortical neurons [63,117,118]. A
number of studies have investigated the therapeutic effects
of BDNF on stroke [91,97,119]. The different delivery
methods appear to influence different aspects of the thera-
peutic effects of BDNF. Delivering BDNF intraventricularly
reduced infarct size after focal cerebral ischemia in rats
[97,119]. In contrast, the intravenous administration of
BDNF did not reduce the final infarct size, but greatly im-
proved motor recovery and induced widespread neuronal
remodeling [91]. Moreover, BDNF was also reported to
protect brain tissues from ischemic injury [120].GDNF
Glial cell line-derived neurotrophic factor (GDNF), a mem-
ber of transforming growth factor super-family named
transforming growth factor-β (TGF-β) [121], is thought to
be the most potent motor neurotrophic factor. It promotes
neuronal survival and regulates migration and differen-
tiation of several different types of peripheral neurons
[98-104], including spinal motor neurons [122] and brain
noradrenergic neurons [121]. When treated with GDNF,
the infarct size and brain edema in the MCAO rats were
significantly reduced [123].
EPO
Erythropoietin (EPO), a hematopoietic cytokine [73],
promotes the differentiation and proliferation of eryth-
roid progenitor cells and improves the survival of matur-
ing cells [105]. The treatment with recombinant human
erythropoietin (rhEPO) after stroke significantly improves
functional recovery and enhances angiogenesis and neuro-
genesis [106]. Furthermore, EPO treatment also provides
neuro-protection after brain injury by decreasing the neur-
onal apoptosis [105]. An HAMC hydrogel encapsulating
EPO decreased neuronal apoptosis and reduced stroke
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possibly due to attenuated inflammatory responses and
enhanced neurogenesis.
NGF
Nerve growth factor (NGF), a member of neurotrophin
family, supports the growth and survival of neural cells
[124]. Since it was first discovered in 1950, NGF has
been explored in the regulation of developing neuro-
logical system [125]. Additionally, it also promotes the
differentiation of stem cells into neurons and the migration
of newly differentiated neurons [126,127]. NGF mediates
neuroprotection through proline-rich Akt substrate
(PRAS) phosphorylation and its interaction with tyrosine
3-monooxygenase/tryptophan 5-monooxygenase activation
protein, theta polypeptide (YWHAQ) and phosphory-lated
Akt (pAkt) [113]. Several studies have investigated the
effects of NGF on stroke. The transplantation of bone mes-
enchymal stem cells (BMSCs) with NGF via the tail vein in
MCAO rats was found to improve neurological function
and promote the differentiation of BMSCs [124]. More-
over, the intranasal administration of NGF in rat MCAO
model improved neurological function with a significant
reduction in the infarct volume and enhancement in sur-
vival and proliferation of progenitor cells [128].
Design considerations for tissue engineering approach
The engineered scaffolds can be rationally designed to
fulfill different regeneration requirements for different
tissues or organs. For effectively treating stroke, some
general criteria need to be met when one chooses a
biomaterial. First of all, an ideal scaffold biomaterial
for stroke tissue regeneration should bear a three-
dimensional structure that provides a highly biocompat-
ible microenvironment favoring cell growth, adhesion,
migration, proliferation and differentiation without elicit-
ing inflammatory responses in vivo [17]. Second, the suffi-
cient number of appropriate cells are required to initiate
regeneration and repopulate the affected neuronal tissue
towards function restoration. Third, a key aspect for func-
tional replacement of damaged brain tissue is to control
the differentiation of transplanted cells into desired phe-
notypes and guide their integration with the host paren-
chyma to replace and replenish the damaged neuronal
population. This can be achieved through the use of appro-
priate growth factors. Thus, the biomaterial is required to
be able to carry and release these factors in vivo, which
should be realized in a controlled manner as the controlled
release has been proven to enhance therapeutic effects.
More importantly, by modifying physical and chemical
traits of the biomaterial, the engineered scaffold can
be designed to possess diverse unique properties. For
example, the dynamics of scaffold biodegradation can
be programmed to synchronize with the host healingprocess [129]. Degradable scaffolds can serve as a tem-
porary delivering vehicle for cells and growth factors
while avoiding the chronic problems caused by long-term
biomaterial implantation. Scaffolds can be designed to
acquire the shape-memory property [129] that allows the
scaffolds to be transplanted through a minimally invasive
approach. Fine modulations of chemical composition of a
scaffold can achieve controlled release of the drugs en-
capsulated within the scaffold in vivo, which would en-
hance the therapeutic effects of these drugs. When such
scaffolds are integrated with cell and cytokine therapies,
their unique properties would help to overcome the in-
herent limitations of these therapies. Additionally, when
one designs a scaffold-based tissue engineering strategy,
the host immune response to the scaffold, host tissue
microenvironment, such as local angiogenesis and vascu-
larization, should be also taken into consideration.
Combining these design considerations into scaffold fabri-
cation would maximize the advantages of the tissue engin-
eering approach for stroke treatment.Conclusions
The need to develop effective therapeutic approaches for
the treatment of stroke is compelling. However, to struc-
turally and functionally restore the damage caused by is-
chemic stroke remains challenging in part because the
brain is the most complex organ [44].
Owing to its powerful potential in facilitating tissue
regeneration, the tissue engineering based strategy is be-
coming another promising approach for ischemic stroke
treatment. A number of different types of stem cells, in-
cluding embryonic stem (ES) cells, iPS cells and NSCs,
have been utilized in cell therapy to repair the injured
brain tissue [90]. One of the major problems associated
with this approach is poor cell survival. We believe that
with the aid of appropriate scaffolds as carriers for cells,
cell survival will be greatly improved in vitro and in vivo.
Some biomaterial scaffolds have been examined in
stroke regeneration, such as collagen, hyaluronan, matrige,
laminin and nanomaterials (Table 2) [16]. The results
indicate biomaterial scaffolds hold promise for promoting
structural and functional restoration of stroke-damaged
neuronal tissue.
Growths factors have been applied in stroke regener-
ation such as BDNF, GDNF and EPO [73,95,97]. These
growth factors can reduce the volume of infarct areas
and induce stem cell differentiation (Table 3). However,
the intravenous administration often results in a thera-
peutic effect that is rather transient and inefficient,
because some growth factors cannot effectively pass
through the blood brain barrier. Localized and sustained
release of growths factors or therapeutic factors via scaf-
folds can be a solution to this problem.
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binations of neuro-protective factors should be explored.
Advances in development of new scaffold materials may
bring tissue engineering treatment one step closer to
clinical applications.
Taken together, the tissue-engineering strategy com-
plements cell and cytokine therapies. The combination
of both can be a valuable alternative for the clinical
treatment of ischemic stroke.
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